BACKGROUND
inflammation, pain, tumor necrosis, dysmenorrhea
PREMENSTRUAL SYNDROME (PMS), TUMOR NECROSIS, PMS, ADVERSE EVENTS, INFLAMMATION, INEFFECTIVE ERYTHROPOIESIS, DYSMENORRHEA, COMPLICATIONS
Premenstrual syndrome (PMS) and dysmenorrhea are common menstrual associated complications which have a negative effect on well‐being and quality of life of women of child bearing age (Bahrami, Avan, et al., There are several parameters that can be used to assess hematological biomarkers derived from a complete blood count (CBC), including absolute counts of white blood cells (WBC), neutrophils as well as red blood cell distribution width (RDW), mean platelet volume (MPV), neutrophil: lymphocyte ratio (NLR), platelet: lymphocyte ratio (PLR), and RDW: platelet ratio (RPR) are novel inexpensive and reproducible indices indicating systemic inflammation in different conditions (Bilgin et al., RDW estimates erythrocytic heterogeneity in volume. Increased RDW reflects ineffective erythropoiesis and associated with higher cytokine levels such as interleukin (IL)‐1, IL‐6 and tumor necrosis factor‐α (TNF‐α) (He et al., HsCRP as an acute‐phase reactant released by the liver is strong index of inflammation. It has been shown that serum hsCRP levels vary during the menstrual cycle in PMS women together with physical and mood manifestations, which advocates the contribution of low‐grade inflammation in the etiology of PMS (Puder et al., Conventional treatment for PMS and dysmenorrhea may induce severe adverse events or be ineffective for relieving pain (Drevon, CUR has been reported to be safe with no serious adverse events even at doses as high as 8–12 g daily for 3 months (Karandish et al., Until now, some clinical trials have explored the effects of CUR administration on serum hsCRP value, but to the best of our knowledge have not assessed its effects on hematological parameters and iron metabolism. Taking into account wide‐ranging positive pharmacological and biological characteristics of CUR while we lack controlled trials among patients with both PMS and dysmenorrhea, the aim of this study was to assess the effects of CUR supplementation on iron profile, inflammatory hematological biomarkers and hs‐CRP levels among apparent healthy young women with PMS and dysmenorrhea.